par Eggermont, A;Suciu, Stefan ;Testori, Alessandro;Kruit, Wim H;Marsden, Jeremy;Punt, Cornelis;Santinami, M.;Sales, François ;Schadendorf, Dirk;Patel, Poulam;Dummer, Reinhard;Robert, Caroline;Keilholz, Ulrich;Yver, Antoine;Spatz, Alain
Référence European journal of cancer, 48, 2, page (218-225)
Publication Publié, 2012-01
Référence European journal of cancer, 48, 2, page (218-225)
Publication Publié, 2012-01
Article révisé par les pairs
Résumé : | Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors. |